A follow-up clinical study in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

05 Mar 2025 New trial record
28 Feb 2025 According to the AIM ImmunoTech Media Release, company announced that Paul Goepfert, MD, of the University of Alabama-Birmingham (UAB), has agreed to act as the Principal Investigator for the company's planned clinical study in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com